Methods for predicting survival in metastatic melanoma patients

US9410205B2 · kind B2 · utility

Assignee

• NEW YORK UNIVERSITY · US

Inventors

• Dusan Bogunovic · New York, US
• Nina Bhardwaj · Montclair, US
• David O'Neill · Flemington, US

Key dates

• Filing date: Feb 17, 2011
• Grant date: Aug 9, 2016
• Expiry date: Oct 12, 2032

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.